Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

 Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Shots:

  • The EMA’s CHMP has recommended the use of casirivimab + imdevimab in patients with confirmed COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19
  • The CHMP scientific opinion supports national decision making within EU states on the use of the antibodies, prior to the future EMA market authorization
  • Regeneron collaborated with Roche to increase the global supply of the antibody cocktail. Regeneron is responsible for the development and distribution of the treatment in the US and Roche is primarily responsible outside the US and has already begun distribution in the EU

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Foursquare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post